A compatibility study between cannabidiol and pharmaceutical excipients commonly used in lipid systems by thermal analysis and fourier transform infrared spectroscopy
Cannabidiol (CBD) is the second largest major component of Cannabis sativa, with therapeutic and non-hallucinogenic activity. However, CBD presents disadvantages such as low oral bioavailability and low water solubility, which makes its administration challenging. Thus, in order to improve its solub...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | bachelorThesis |
| Idioma: | pt_BR |
| Publicado em: |
Universidade Federal do Rio Grande do Norte
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/handle/123456789/35734 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | Cannabidiol (CBD) is the second largest major component of Cannabis sativa, with therapeutic and non-hallucinogenic activity. However, CBD presents disadvantages such as low oral bioavailability and low water solubility, which makes its administration challenging. Thus, in order to improve its solubility and oral bioavailability, lipid-based formulations, such as emulsified systems, have been developed. Nevertheless, there is a lack of information about CBD compatibility with the oils and surfactants used in emulsified systems. Also, the lipid content of these formulations are not reported. Thus, the aim of this work was to evaluate the compatibility between CBD and excipients commonly used in the production of emulsified systems in order to provide information for the development of CBD lipid formulations. CBD, Tween® 20, Tween® 80, Span® 80, and Span® 85, Miglyol® 812 N, and sesame, soybean, olive, and safflower oils were analyzed separately and in binary mixtures (CBD:excipient) at a 1:1 (w/w) ratio by DSC-TGA simultaneous analysis. The samples were further scanned in an ATR-FTIR between 700 and 4000 cm-1. Pearson's correlation was added through a docking script using R language. All CBD:oil binary mixtures showed similar thermal behavior, except for Miglyol® 812 N. The absence of the oxidation peak in the binary mixtures of CBD with oils and surfactants allowed us to infer that they protected CBD from oxidation. Moreover, the mass loss of the binary mixtures displayed slower rates when compared to CBD itself, which confirm the improvement of the thermal profile of CBD by addition of other emulsion components of the formulation. FTIR analysis by Pearson’s correlation confirmed minor interactions between CBD:excipient that do not represent pharmaceutical incompatibilities. All tested natural oils and surfactants were compatible and, therefore, suitable for prospect emulsified system formulations containing CBD. |
|---|